Real-world experience with second-generation S1P receptor modulators in multiple sclerosis

Key Points

• Second-generation S1P receptor modulators demonstrate promising therapeutic efficacy in multiple sclerosis.
• In a cohort study involving diverse clinical settings, 70% of participants reported reduced relapse rates after treatment.
• Treatment involves a specific regimen of immunomodulation using S1P receptor modulators, aiding in decreasing disease activity.
• Findings suggest ongoing monitoring is essential due to potential adverse events associated with S1P receptor modulators.